Browse by Audience
Skip to content
Papers of the Week
Gut immunomodulation with vedolizumab prior to allogeneic hematopoietic stem cell transplantation in pediatric patients with inflammatory bowel disease.
Authors
Chopra Y, Acevedo K, Muise A, Frost K, Schechter T, Krueger J, Ali M, Chiang KY, Kim VY, Grunebaum E, Wall DAbstract
Inborn errors of immunity (IEI) are often associated with inflammatory bowel disease (IBD). IEI can be corrected by allogeneic hematopoietic stem cell transplantation (HSCT) however peri-transplantation intestinal inflammation may lead to increased risk of gut graft-versus-host disease (GVHD). Vedolizumab inhibits the homing of lymphocytes to the intestine and may attenuate gut GVHD, yet its role in preventing GvHD in pediatric patients with IEI-associated IBD has not been studied.